Armata Pharmaceuticals, Inc. has received a $15 million award for a three year program from the U.S. DoD to partially fund a Phase 1b/2, randomized, double-blind, placebo-controlled, dose escalation clinical study of Armata’s therapeutic phage-based candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia infections. Todd R. Patrick, Chief Executive Officer of Armata Pharmaceuticals, said, “This funding from the DoD validates the potential of phage-ba...